Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3814-3819

  Huang, Yu Tsung ^a,b   Liu, Chia Ying ^a   Liao, Chun Hsing ^a   Chung, Kuei Pin ^b   Sheng, Wang Huei ^b   Hsueh, Po Ren ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; TAIWAN; BLOOD; CROSS INFECTION; DRUG EFFECTS; HEMATOLOGIC DISEASE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOLOGIC DISEASES; HUMANS; MICROBIAL SENSITIVITY TESTS; TAIWAN;

EID: 84903192486     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01035-13     Document Type: Article

References (29)

1. Arendrup MC. 2010. Epidemiology of invasive candidiasis. Curr. Opin. Crit. Care 16:445-452. http://dx.doi.org/10.1097/MCC.0b013e32833e84d2.
2. Hsueh PR, Graybill JR, Playford EG, Watcharananan SP, Oh MD, Ja'alam K, Huang S, Nangia V, Kurup A, Padiglione AA. 2009. Consensus statement on the management of invasive candidiasis in intensive care units in the Asia-Pacific Region. Int. J. Antimicrob. Agents 34:205-209. http://dx.doi.org/10.1016/j. ijantimicag.2009.03.014.
3. Chen CY, Huang SY, Tsay W, Yao M, Tang JL, Ko BS, Chou WC, Tien HF, Hsueh PR. 2012. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010. Int. J. Antimicrob. Agents 40:533-538. http://dx.doi.org/10.1016/j.ijantimicag.2012.07.022.
4. Chen LY, Kuo SC, Wu HS, Yang SP, Chan YJ, Chen LK, Wang FD. 2013. Associated clinical characteristics of patients with candidemia among different Candida species. J. Microbiol. Immunol. Infect. 46:463-468. http://dx.doi.org/ 10.1016/j.jmii.2012.08.001.
5. Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, Chu CC, Hsueh PR, Chang SC, Chen YC. 2014. Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. J. Microbiol. Immunol. Infect. 47: 95-103. http://dx.doi.org/10.1016/j.jmii.2012. 08.025.
6. Tsai CC, Lay CJ, Wang CL, Lin ML, Yang SP. 2011. Prognostic factors of candidemia among nonneutropenic adults with total parenteral nutrition. J. Microbiol. Immunol. Infect. 44:461-466. http://dx.doi.org/10.1016/j.jmii.2011. 04.002.
7. Ruan SY, Hsueh PR. 2009. Invasive candidiasis: an overview from Taiwan. J. Formos. Med. Assoc. 108:443-451. http://dx.doi.org/10.1016/S0929-6646(09) 60091-7.
8. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846-2856. http://dx.doi.org/10.1128/JCM.00937-12.
9. Cuenca-Estrella M, Gomez-Lopez A, Alastruey-Izquierdo A, Bernal-Martinez L, Cuesta I, Buitrago MJ, Rodriguez-Tudela JL. 2010. Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution reference methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates. J. Clin. Microbiol. 48:1782-1786. http://dx.doi.org/10.1128/JCM.02316- 09.
10. Alexander BD, Byrne TC, Smith KL, Hanson KE, Anstrom KJ, Perfect JR, Reller LB. 2007. Comparative evaluation of Etest and Sensititre YeastOne panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J. Clin. Microbiol. 45:698-706. http://dx.doi.org/10.1128/JCM.01840-06. (Pubitemid 46427680)
11. Espinel-Ingroff A, Pfaller M, Messer SA, Knapp CC, Holliday N, Killian SB. 2004. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42:718-721. http://dx.doi.org/10.1128/JCM.42.2.718-721.2004. (Pubitemid 38222652)
12. Cantón E, Pemán J, Hervás D, Iñiguez C, Navarro D, Echeverría J, Martínez-Alarcón J, Fontanals D, Gomila-Sard B, Buendía B, Torroba L, Ayats J, Bratos A, Sánchez-Reus F, Fernández-Natal I, FUNGEMYCA Study Group. 2012. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method. J. Clin. Microbiol. 50:3921-3926. http://dx.doi.org/10.1128/JCM.01730-12.
13. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BBD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol. Infect. Dis. 70:330-343. http://dx.doi.org/10.1016/j.diagmicrobio.2011.03.002.
14. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176. http://dx.doi.org/10. 1016/j.drup.2011.01.004.
15. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45-50. http://dx.doi.org/10.1016/j.diagmicrobio.2010.08.013.
16. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. 2011. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J. Clin. Microbiol. 49: 630-637. http://dx.doi.org/10. 1128/JCM.02161-10.
17. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56. http://dx.doi.org/10.1128/JCM.01590-09.
18. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. 2011. Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. J. Clin. Microbiol. 49:3800-3804. http://dx.doi.org/10.1128/JCM.05047-11.
19. Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Fuller J, Ghannoum M, Jones RN, Lockhart SR, Martin-Mazuelos E, Melhem MS, Ostrosky-Zeichner L, Pappas P, Pelaez T, Peman J, Rex J, Szeszs MW. 2012. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J. Clin. Microbiol. 50:2040-2046. http://dx.doi.org/10.1128/JCM.00248-12.
20. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth informational supplement M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57:5836-5842. http://dx.doi.org/10. 1128/AAC.01519-13.
22. Lai CC, Chu CC, Wang CY, Tsai HY, Cheng A, Lee YC, Huang YT, Liao CH, Hsueh PR. 2012. Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int. J. Antimicrob. Agents 40:349-353. http://dx.doi.org/10.1016/j.ijantimicag.2012.05.024.
23. Wang H, Xiao M, Chen SC, Kong F, Sun ZY, Liao K, Lu J, Shao HF, Yan Y, Fan H, Hu ZD, Chu YZ, Hu TS, Ni YX, Zou GL, Xu YC. 2012. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J. Clin. Microbiol. 50:3952-3959. http://dx.doi.org/10.1128/JCM.01130-12.
24. Ruan SY, Chu CC, Hsueh PR. 2008. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates. Antimicrob. Agents Chemother. 52:2919-2922. http://dx.doi.org/10.1128/AAC.00323-08.
25. Hsueh PR, Lau YJ, Chuang YC, Wang JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT. 2005. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob. Agents Chemother. 49:512-517. http://dx.doi.org/10.1128/AAC.49.2.512-517.2005.
26. Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR. 2008. Candida glabrata fungaemia in intensive care units. Clin. Microbiol. Infect. 14:136-140. http://dx.doi.org/10.1111/j.1469-0691.2007.01892.x.
27. Liu W, Tan J, Sun J, Xu Z, Li M, Yang Q, Shao H, Zhang L, Liu W, Wan Z, Cui W, Zang B, Jiang D, Fang Q, Qin B, Qin T, Li W, Guo F, Liu D, Guan X, Yu K, Qiu H, Li R, the China-SCAN team. 2014. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study. J. Antimicrob. Chemother. 69:162-167. http://dx.doi.org/10.1093/jac/dkt330.
28. Eschenauer GA, Nguyen MH, Shoham S, Vazquez JA, Morris AJ, Pasculle WA, Kubin CJ, Klinker KP, Carver PL, Hanson KE, Chen S, Lam SW, Potoski BA, Clarke LG, Shields RK, Clancy CJ. 6 January 2014. Real-world experience with echinocandin MICs against Candida species: a multi-center study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.02163-13.
29. Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, Kontoyiannis DP, Giladi M, Israeli Candidemia Study Group. 2012. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob. Agents Chemother. 56:2518-2523. http://dx.doi.org/10.1128/AAC.05947-11.